Search Results - "Suter, M.B"

Imatinib (IM) discontinuation in chronic myeloid leukemia (CML): A pharmacogenetic score for patients with durable complete molecular response (CMR) by Campiotti, L, Ferrari, M, Orlandi, E.M, Suter, M.B, Squizzato, A, Guasti, L, Marino, F, Cosentino, M

“…An abstract of a study by Campiotti et al assessing the relationship between CMR and pharmacogenetics of imatinib (IM) is presented. We enrolled 59 consecutive…”
Get full text

225 - Imatinib (IM) discontinuation in chronic myeloid leukemia (CML): A pharmacogenetic score for patients with durable complete molecular response (CMR) by Campiotti, L., Ferrari, M., Orlandi, E.M., Suter, M.B., Squizzato, A., Guasti, L., Marino, F., Cosentino, M.

Get full text

211P Drug-drug interactions and their impact on clinical outcomes and adverse events in hormone receptor (HR)+/HER2- advanced breast cancer patients treated with ribociclib + letrozole: Insights from the BioltaLEE trial by Botticelli, A., Arpino, G., Bianchini, G., Malorni, L., Caputo, R., Zambelli, A., Puglisi, F., Del Mastro, L., Colleoni, M.A., Montemurro, F., Bianchi, G.V., Paris, I., Suter, M.B., Scagnoli, S., Marchetti, P., De Laurentiis, M.

Get full text

199P Correlation of circulating tumor DNA (ctDNA) or thymidine kinase activity (TKa) dynamic patterns with tumor response in patients (pts) with hormone receptor (HR)+ human epidermal growth factor 2 (HER2)– advanced breast cancer (ABC) on ribociclib (RIB) + letrozole (LET) in BioItaLEE trial by Arpino, G., Bianchini, G., Malorni, L., Caputo, R., Zambelli, A., Puglisi, F., Del Mastro, L., Colleoni, M.A., Montemurro, F., Bianchi, G.V., Paris, I., Allegrini, G., Tamberi, S., Cazzaniga, M.E., Orditura, M., Zamagni, C., Suter, M.B., Fenderico, N., De Laurentiis, M.

Get full text